Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT04648384 |
Other study ID # |
Protein Supplementation |
Secondary ID |
|
Status |
Completed |
Phase |
N/A
|
First received |
|
Last updated |
|
Start date |
March 20, 2016 |
Est. completion date |
October 20, 2019 |
Study information
Verified date |
November 2020 |
Source |
University of Sao Paulo |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
The proteins of human breast milk are the most important endocrine signaling system that
promotes neonatal growth by increasing the release of insulin, insulin-like growth factor-1
(IGF-1), and the leucine-mediated mammalian target of rapamycin complex 1- (mTORC1) signaling
of pancreatic β-cells. Remarkably, the branched-chain amino acids (BCAAs) leucine,
isoleucine, and valine are involved in the growth-promoting effects of milk, protein
biosynthesis, and metabolism because they physiologically stimulate insulin secretion The
present study sought to investigate the effects of the combination of whey protein and casein
in the ratio of 80:20 ("whey protein: casein" or "casein: whey protein") as breast milk
proportion on the peak and the period of the permanence of branched-chain amino acids in the
blood circulation, final metabolites of protein metabolism and delayed onset muscle soreness
(DOMS) after a single bout of fasting or a resistance exercise session.
Description:
The present study investigated the effects of the association of WP and casein in the ratio
of 80:20, a similar ratio of human breast milk, on blood branched-chain amino acids (BCAAs)
profile by HPLC technique, markers of protein metabolism (creatinine, urea, and urine
nitrogen) and delayed onset muscle soreness (DOMS) after a single bout of resistance
exercise. A double-blind, crossover and acute study was conducted with ten men (age 29 ± 8 y;
BMI: 25.4 ± 2.9 Kg/m2; 77 ± 12 kg; 1.74 ± 0.09 m) that were randomly assigned to five
supplementation treatments: WP - whey protein; CAS - casein; WP/CAS - 80% WP/20% CAS; CAS/WP
- 80% CAS/ 20% WP; PLA - placebo. Participants were submitted to the following evaluations:
performance sessions, blood collection for each session for the BCAAs profile determination,
two food records, 3-days assessment of DOMS (24h, 48h, 72h) after each treatment.